Illuminare Biotechnologies is a clinical stage biotechnology company focused on intra-operative nerve visualization to reduce the risk of nerve damage. Our proprietary lead candidate, Illuminare-1, is a small molecule with an immediate onset of action and sustained duration of nerve illumination. Illuminare-1 just finished completing a first-in-human trial in radical prostatectomy at Memorial Sloan Kettering Cancer Center to demonstrate safety and initial efficacy improving visualization of nerves (more information about clinical trial). The company expects to enter Phase 2 in 2025.
Company Details
- Employees
- 2
- Address
- 325 Saint Marks Ave, Brooklyn,new York 11238,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://illuminarebio.com/
- HQ
- Brooklyn, New York
Illuminare Biotechnologies Questions
Illuminare Biotechnologies's website is https://illuminarebio.com/
Illuminare Biotechnologies's LinkedIn profile is https://www.linkedin.com/company/illuminare-biotechnologies
Illuminare Biotechnologies has
2 employees.
View email and phone details for 2
employees at Illuminare Biotechnologies.
Illuminare Biotechnologies's industry is
Biotechnology Research
Illuminare Biotechnologies's top competitors are
Oral Biolife Inc.,
Meta Pharmaceuticals Inc.,
Innopeutics Corporation,
Topelia,
Abm Therapeutics,
Help Therapeutics,
Pll Therapeutics,
Persica Pharmaceuticals Limited,
Sanobio Therapeutics,
Sansho Co., Ltd..
Illuminare Biotechnologies's categories are Biotechnology Research
